secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-04-25T23:59:59+00:00
Accession:  0000950170-23-014424
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics replaces CEO and CFO; Blischak appointed CEO effective May 16
--------------------------------------------------------------------------------

- CEO Mark Smith and COO Marc Blaustein terminated without cause, effective May 15, 2023; Smith resigns from board.
- Matthew P. Blischak named CEO effective May 16; base salary $400k, target bonus 40%, option grant of 962,899 shares.
- Lance Thibault (Danforth Advisors) named CFO effective May 16; paid hourly $525.
- Former executives to remain as consultants under advisory agreements.
- Company emphasizes foundational IP estate (over 70 issued patents) as key asset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/0000950170-23-014424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023014424/fnch-20230421.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-014424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer